Daniel Auclair

This account is verified. Learn more

@AuclairDan

Working hard to bring novel therapies, drug combinations and diagnostics to blood cancer patient.Tweets are my own #precisionmedicine #mmsm #leusm #lymsm

Connecticut Joined January 2017

2.1K Following 4.7K Followers 9.4K Posts

Latest posts 5

Daniel Auclair @AuclairDan 6d

The #ASH26 abstracts are now live! A lot of great science to digest, it will be another fantastic meeting. Thoughts and usual top lists to follow #mmsm #lymsm # amlsm #leusm @mtmdphd @RahulBanerjeeMD @szusmani

ASH @ASH_hematology 6d

📢 The wait is over: Abstracts for the 68th ASH Annual Meeting and Exposition are live!

More than 6,300 abstracts have been accepted for oral and poster presentations at #ASH26.

Browse now: ow.ly/5VCp5103LAa

#Hematology #HemeOnc

View quoted post on X

Daniel Auclair @AuclairDan Sep 27

Loved it @JoshuaRichterMD ! It is all about bioreology. Still a lot of work to do on the quick relapsing bad disease front #IMS26 #mmsm

Reetu Jain @ReetuJain19 Sep 26

@JoshuaRichterMD , @DrPMPGI @Myeloma_Society ..The oreo cookie example..drove straight the message...

View quoted post on X

Daniel Auclair @AuclairDan Sep 26

Now let’s continue innovating and pushing forward to improve the outcome for the High-Risk patients. I am dreaming of a day when we don’t have SR and HR curves #IMS26 #mmsm

Mohamad Mohty Verified account @Mohty_EBMT Sep 25

This is the new benchmark ! Présented at #IMS2026 @TheIACH

View quoted post on X

Daniel Auclair @AuclairDan Sep 26

100% agree @VincentRK. Beyond infections, high-risk disease also an important contributor. @szusmani MSK team published on 503 cases having received a PERSEUS-like regimen and HR cases per new IMS-IMWG still doing poorly despite deeper early MRD negativity
ashpublications.org/bloodadvances/…

Vincent Rajkumar Verified account @VincentRK Sep 26

PERSEUS is the gold standard benchmark outcome for Newly Diagnosed Myeloma

6 year overall survival: 86%
6 year PFS 81%
with quad induction and Dara-Len maintenance.

As we test bispecifics, ADCs, CARTs etc, any new approach should be better. A new therapy CANNOT have even 5% all cause mortality in first 4 years.

There is no room for error with infection related mortality. No early drop off. No learning curve. As a field we have to establish preventive measures to prevent infection related deaths. #IMS26

View quoted post on X

Daniel Auclair @AuclairDan Sep 24

Very interesting Competing-Risk analysis of MajesTEC-3 presented by @End_myeloma at #IMS26 . Tec-Dara OS benefit driven by suppression of disease progression while NRM remains comparable over time.